CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C.

20231, on

**PATENT** 

Attorney Docket No. 22488-710

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application

Inventor(s): Jian -Yun Dong, et a

Application No.: 09/600,521

Filed: November 5, 1999

Title Method of Treating Tumors Using Fas-Induced)

**Apoptosis** 

PATENT APPLICATION

Art Unit: 1642

Examiner: Not Yet Assigned:

WAY 2 3 2002 TECH CENTER 1600/2900

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Commissioner for Patents Washington, D.C. 20231

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

-1-

$\boxtimes$	This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):								
		(1)	It is being filed within 3 months of the application filing date and is other than a continuous prosecution application under § 1.53(d)  OR						
		(2)	It is being filed within 3 months	s of entry of a national stage					
	$\boxtimes$	(3)		date of the first Office Action on the merits					
		(4)		ng of a first Office Action after the filing of a request for 1.114.					
	37 C.F.R. $\S1.97(c)$ . If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in $\S1.491$ in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under $\S1.113$ or a notice of allowance under $\S1.311$ , then:								
	a certification as specified in §1.97(e) is provided below; or								
		a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.							
	37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:								
	A.	a certif	fication as specified in §1.97(e) is	completed below; and					
	В.	a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; and							
	C.		f \$130.00 as set forth in §1.17(i)( nt of other papers filed together v	1) is authorized below, enclosed, or included with the vith this statement.					
	Fee Authorization. The Commissioner is hereby authorized to charge the above-referenced fees of \$0 and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 23-2415 (Docket No.22488-710).								
				Respectfully submitted,					
				WILSON SONSINI GOODRICH & ROSATI					
Dated:	m	ay	16,2002	By: Shirley Chen, Reg. No. 44,608					
650 Pag	ge Mill I	Road							

650 Page Mill Road Palo Alto, CA 94304-1050 (650) 493-9300 Customer No. 021971

	~							
						SHEE	Т 1 OF	
INFORM	ATION DISÇ	OSBIRE	ATTY. DOCKET NO.	SEI				
	CITATION	TC10	22488-710 09/600,521					
	PTO-1449 MA	APPLICANT Jian-Yun Dong						
	THE STATE OF THE S		FILING DATE 11/5/1999	GR	OUP 1642			
	4	TRADEMAT U.S	. PATENT DOCUMENTS					
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING	G DATE	
						5-11 W		
					MAY	3 200	12	
		FORE	EIGN PATENT DOCUMENTS	5	TECH CENTE	R 1600	/oo -	
EXAMINER'S	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
INITIALS						YES	NO	
	WO 97/33617	18/9/1997	PCT	A61K	39/395			
	WO 98/37185	27/8/1998	PCT	C12N	15/00			
	0675200 A1	04/10/1995	ЕРО	C12N	15/19			
	WO 01/79495	25/10/2001	PCT	C12N	15/12			
	OTHER DO	CUMENTS (I	ncluding Author, Title, Date, I	Pertinent Pa	ges, Etc.)			
			of Fas Ligand Induces Tunor Reg op. 13862-13867.	ression in vi	vo"; December	1997; Pra	c. Natl.	
	Cell Death (Apo	optosis) in Ente	elial Lympohocytes in Celiac M rocytes? Histochemical Demons "; October 1998; Journal of Pedi	stration of Pe	erforins in Cyton	lasmic G	ranules	
	Ronald P. Leon Sci. USA; Vol.	; "Adenoviral-N 95, pp. 13159-1	Mediated Gene Transfer in Lymp 13164.	hocytes"; O	ctober 1998; Pro	c. Natl. A	Acad.	
	GN Barber; "Host Defense, Viruses and Apoptosis"; 2001; Cell Death and Differentiation; pp. 113-126.							
	C. Belka; "Sensitization of Resistant Lymphoma Cells to Irradiation-Induced Apoptosis by the Death Ligand TRAIL"; 2001 Oncogene; pp. 2190-2196.							
			Activity and Bystander Effects RAIL) Gene; April 15, 2001; Car				i	
	Shi-Qiong Xu " Biochemical and	P21 WAF1/CIP1 Inh d Biophysical R	nibits Initiator Caspase Cleavage Research Communications 269; p	by TRAIL I p. 179-190.	Death Receptor I	DR4"; 20	00;	
			al-Mediated Transfer of the TNF ell Apoptosis; 2000; The Americ					
	T.S. Griffith et	al "Adenovira	l-mediated gene transfer of TRA	II. induces t	umor cell aponte	neie" An	ril	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

**EXAMINER** 

2000, Vol 14, No. 6, p. A1003 (abstract).

SHEET 2 OF 3

INFORMA	TION DISÇKO	STURER.	ATTY. DOCKET NO.	s	ERIAL NO.				
	CITATION	~ 'c)	22488-710		09/600,521				
	PTO-1449 MAY	2 0 2002	APPLICANT Jian-Yun Dong						
	Ø.		FILING DATE 11/5/1999	C	GROUP 1642				
	67	RADENA U.S	. PATENT DOCUMENTS						
EXAMINER'S INITIALS	PATENT NO. DATE		NAME	CLAS	S SUBCLASS	FILING DATE			
					REO				
		FORE	EIGN PATENT DOCUMENTS		TOWN 2	3 2002			
EXAMINER'S INITIALS	PATENT NO. DATE		COUNTRY		s Edderse	TRANS	NO		
		<u> </u>							
	OTHER DO	CUMENTS (	Including Author, Title, Date, P	Pertinent	Pages, Etc.)				
X. Wei, "Killing effect of TNF-related apoptosis including ligand regulated by tetracycline on gastric can cell line NCI-N87", Database EMBASE online – Elsevier Science Publishers and World Journal of Gastroenterology, 2001 7/4, pp. 559-562 (abstract)									
Adrian E. Morelli, et al., "Neuronal and glial cell type-specific promoters within adenovirus recorrestrict the expression of the apoptosis-inducing molecule Fas ligand to predetermined brain cell abolish peripheral liver toxicity", 1999, Journal of General Virology, Vol. 80, pp. 571-583.							inants es, and		
	S. Rubinchik, et inducible expres 7, No. 10, pp. 87	sion system",	ral vector which delivers FasL-G May 2000, Database BIOSIS onlet).	FP fusior line – Bio	n protein regulated oscicences Informat	by the tet tion Servi	ce, Vol		
Mano Toshiaki, et al., "Expression of Wild-Type and Noncleavable Fas Ligand by Tetracycline-Regula Adenoviral Vectors to Limit Intimal Hyperplasia in Vascular Lesions", August 2000, Human Gene Therapy, Vol 11., No. 12, pp. 1625-1635.							ulated		
	T. Gura, "How TRAIL Kills Cancer Cells But Not Normal Cells", 1977, Cancer Research, Vol. 77, p. 768.								
W. Roth, et al. Todesliganden/Todesrezeptoren als Angriffspunkt der somatischen Gentherapie Maligner Gliome; March 1999; Neuroforum, Vol. 5, No. 3; pp. 87-92. Abstract written in English on p. 87.									
	prostate cancer	cells", Februar	denovirus-mediated expression or y 1999, Database BIOSIS online oruary 1999, Vol. 6, No. 2, pp. 17	- Biosci	ences Information	sis of hun Service a	nan nd Cell		
	Magdalene K. S T47D human br Research Annua	east cancer ce	"Induction of apoptosis by adeno lls", March 2000, Proceedings of 37.	virus-me the Ame	diated over-express rican Association f	sion of Bl or Cance	RCA1 in		
EXAMINER			DATE CONSIDERED						

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

						ULL	1 3 Or 3			
INFORMATION DISCLOSURES CITATION			ATTY. DOCKET NO.	SE	SERIAL NO.					
			22488-710	09/600,521						
	PTO-1449	2 0 7002 35	APPLICANT Jian-Yun Don	g						
	E A	CERICE!	FILING DATE 11/5/1999	NG DATE 11/5/1999 GROUP 1642						
		U.S.	PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS SUBCLASS		FILING DATE				
			,		MAY 2	2002				
					TECH CENTER	2002				
		FORE	IGN PATENT DOCUMENTS		- OF INTER	1600/29	900			
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION				
INITIALS						YES	NO			
				ļ						
	OTHER DO	CUMENTS (I	ncluding Author, Title, Date, Pe	ertinent P	ages, Etc.)					
A.T. Larregina, et al., "FasL induces Fas/Apol-mediated apoptosis in human embryonic kidney 293 cells routinely used to generate E1-deleted adenoviral vectors", April 1998, Database BIOSIS online – Biosciences Information Service and April 1998, Gene Therapy, Vol. 5, No. 4, pp. 563-568 (abstract).										
	Zhang, Huang-Ge, et al.; "Application of a Fas Ligand Encoding a Recombinant Adenovirus Vector for Prolongation of Transgene Expression; March 1998, Journal of Virology, Vol. 72, No. 3; pp. 2483-2490.									
							., .,			
···										
EXAMINER			DATE CONSIDERED							

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.